These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19616955)

  • 1. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
    Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
    Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
    J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
    Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
    Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
    Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.
    Sato N; Takahashi T; Shibata T; Haga Y; Sakuraba A; Hirose M; Sato M; Nonoshita K; Koike Y; Kitazawa H; Fujino N; Ishii Y; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2003 Feb; 46(5):666-9. PubMed ID: 12593644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.
    Tamura Y; Omori N; Kouyama N; Nishiura Y; Hayashi K; Watanabe K; Tanaka Y; Chiba T; Yukioka H; Sato H; Okuno T
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5498-502. PubMed ID: 22853998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.
    Ando M; Sekino E; Haga Y; Moriya M; Ito M; Ito J; Iwaasa H; Ishihara A; Kanatani A; Ohtake N
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5186-90. PubMed ID: 19632840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.
    Sato N; Jitsuoka M; Shibata T; Hirohashi T; Nonoshita K; Moriya M; Haga Y; Sakuraba A; Ando M; Ohe T; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2008 Aug; 51(15):4765-70. PubMed ID: 18637668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.
    Tamura Y; Hayashi K; Omori N; Nishiura Y; Watanabe K; Tanaka N; Fujioka M; Kouyama N; Yukimasa A; Tanaka Y; Chiba T; Tanioka H; Nambu H; Yukioka H; Sato H; Okuno T
    Bioorg Med Chem Lett; 2013 Jan; 23(1):90-5. PubMed ID: 23206862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
    Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.
    Sato N; Jitsuoka M; Ishikawa S; Nagai K; Tsuge H; Ando M; Okamoto O; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1670-4. PubMed ID: 19233647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist.
    Omori N; Kouyama N; Yukimasa A; Watanabe K; Yokota Y; Tanioka H; Nambu H; Yukioka H; Sato N; Tanaka Y; Sekiguchi K; Okuno T
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2020-3. PubMed ID: 22300657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
    Levens NR; Della-Zuana O
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.